At a glance
ClinicalIndex Comparison RecordN/ACompleted· 27 enrolled
Drug / intervention
Ozurdex +1 moredrug
Likely dose
Ozurdex 0.7mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparative Study of Initial Ozurdex (Dexamethasone Implant) Versus Avastin (Bevacizumab) in the Treatment of Macular Edema Following Central Retinal Vein Occlusion (CRVO)
In Brief
A clinical study evaluating Ozurdex and Avastin for Macular Edema and Central Retinal Vein Occlusion. Completed, enrolled 27 participants across 4 sites.
Detailed Summary
The purpose of this study is to compare visual improvement and total number of intraocular injections in eyes with macular edema following central retinal vein occlusion (CRVO)after initial treatment with Ozurdex (dexamethasone implant) or Avastin (bevacizumab).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Edema, Central Retinal Vein Occlusion
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
First PostedNov 2010
Primary CompletionSep 2014
TodayJul 2026
First PostedNov 1, 2010
Enrollment StartSep 1, 2010
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 15.7 years ago
Interventions
Ozurdexdrug
Ozurdex, 0.7mg dexamethasone
Avastindrug
Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.